/ /

  • linkedin
  • Increase Font
  • Sharebar

    FOURIER Clinical Outcomes Trial Results: Center Stage at ACC.17

    FOURIER was a double blind randomized placebo-controlled trial with 27,564 patients conducted at 1242 sites in 49 countries.

    • Patients were diagnosed with atherosclerotic cardiovascular disease (ASCVD), baseline LDL ≥70 mg/dL, and already receiving statins.
    • Patients were randomized to placebo or evolocumab (420 mg/month or 140 mg every other week)
    • Two year outcomes presented at the American College of Cardiology (ACC) 2017 Scientific Sessions, March 2017, in Washington, DC.
    • Primary Endpoint: composite of CV death, MI, stroke, hospitalization for unstable angina, coronary revascularization
    • Secondary Endpoint: composite of CV death, MI, stroke

    Find study details in the slides that follow.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available